Investors have long been reading about cannabis stocks to buy. However, stocks in the sector have largely remained speculative plays. A key reason is regulatory headwinds that have impacted growth. At the same time, cannabis companies have faced sustained cash burn. However, there seems to be good news on both fronts. At least 40 countries have fully or partially legalized cannabis. Most recently, Germany legalized the adult use of cannabis. In the United States, the reclassification of cannabis as a Schedule III drug is impending. Further, most Americans support the legalization of cannabis at the federal level. Therefore, as regulatory headwinds wane, it’s a good time to consider exposure to quality cannabis stocks. I must add that some of the best cannabis companies have achieved or are close to achieving EBITDA level break-even. If growth accelerates due to friendly regulations, margin expansion will likely follow. InvestorPlace - Stock Market News, Stock Advice & Trading Tips With these positives, let’s talk about three cannabis stocks to buy for multibagger returns. Cronos Group (CRON) A close-up shot of hands holding a grinder with cannabis buds in the background representing aurora stock. cannabis stocks to buy Source: Shutterstock Cronos Group (NASDAQ:CRON) is among the most undervalued cannabis stocks to buy for multibagger returns. The cannabis company’s current cash buffer of $855 million is almost equal to its market valuation. It’s likely that Cronos will use the cash to pursue aggressive organic and acquisition-driven growth in the next 24 months. In fact, Cronos has expanded into new geographies in recent years, including Germany, Australia, and the United Kingdom. In a recent development, Cronos announced it would provide a $51 million secured non-revolving credit facility to GrowCo (50% ownership) to fund facility expansion. The objective is to address the increased global demand for high-quality cannabis flowers. For Q1 2024, Cronos reported healthy revenue growth of 30% on a year-on-year basis to $25.3 million. Considering the recent entry into new geographies, revenue growth will likely accelerate, supporting significant upside for CRON stock from undervalued levels. Tilray (TLRY) Close view of Tilray (TLRY) logo on a smart phone. Tilray specializes in cannabis research, cultivation, processing and distribution. TLRY stock Source: Lori Butcher / Shutterstock.com Tilray Brands (NASDAQ:TLRY) stock has been subdued for an extended period. Given the business developments, I believe a strong breakout on the upside is impending. Last month, Tilray announced an at-the-market program of $250 million. The company intends to use the proceeds to fund strategic and accretive acquisitions in the U.S. and internationally. This is the anticipation of the reclassification of cannabis as a Schedule III drug in the U.S. It’s worth noting that for Q3 2024, Tilray reported a global cannabis net revenue increase of 33% on a year-on-year basis. However, international cannabis growth for the period was 44%. Recently, Tilray launched Broken Coast EU-GMP-certified medical cannabis products in Australia. The medicinal cannabis segment will likely remain a growth driver, expanding its presence in Europe and emerging markets. At the same time, Tilray has established itself as the fifth largest craft beer brewer in the U.S. This diversification has helped establish a strong strategic infrastructure for cannabis expansion on possible federal-level legalization. Canopy Growth Corporation (CGC) Closeup of mobile phone screen with logo lettering of cannabinoid company canopy growth cannabis, blurred marijuana in the background. CGC stock. Source: Ralf Liebhold / Shutterstock Canopy Growth (NASDAQ:CGC) stock had surged to closing highs of $14.9 towards the end of April. However, a sharp correction has occurred, and CGC stock trades at $7. The downside is a good opportunity to accumulate. It’s worth noting that at the beginning of the month, Canopy announced an equity offering of $250 million. Dilution is one of the reasons for sharp corrections, in addition to profit bookings after a massive rally. However, leaving the near-term price action aside, Canopy is positioned for accelerated growth. An important point to note is that Canopy has a strong presence in the German cannabis market. With cannabis legalization in the country, the company is positioned for accelerated growth. Canopy is also building a presence in the United States in anticipation of friendly regulations. In Q1 2025, Canopy USA initiated the acquisitions of Mountain High Products, Wana Wellness, The Cima Group, and Lemurian. These acquisitions are likely to be completed in the first half of FY2025. On the date of publication, Faisal Humayun did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Faisal Humayun is a senior research analyst with 12 years of industry experience in the field of credit research, equity research and financial modeling. Faisal has authored over 1,500 stock specific articles with focus on the technology, energy and commodities sector. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post 3 Cannabis Stocks to Buy Before Regulations Get Super Friendly appeared first on InvestorPlace.
3 Cannabis Stocks to Buy Before Regulations Get Super Friendly
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...